Palomo Atance E, Ballester Herrera M J, Márquez de La Plata M A, Medina Cano E, Carmona Vilchez R M
Unidad de Endocrinología Pediátrica, Hospital General de Ciudad Real, Ciudad Real, Spain.
An Pediatr (Barc). 2011 Feb;74(2):122-5. doi: 10.1016/j.anpedi.2010.10.002. Epub 2010 Dec 18.
Reduced mobility and glucocorticoids as adjunctive therapy causes osteoporosis in Duchenne muscular dystrophy. Alendronate has been used in childhood osteoporosis of other aetiologies with good results and no adverse effects.
Three patients with Duchenne dystrophy, symptoms of bone involvement (prior history of generalized bone pain and fractures) and bone mineral density (BMD) by dual-energy X-ray absorptiometry with Z-score ≤-2 SD. Treatment with oral alendronate was initiated (10mg/day).
There was an increase in lumbar (L2-L4) BMD in all cases, with improvement of bone pain. No fractures and adverse effects were observed during follow up.
Oral alendronate produces an increase in BMD in these patients, with good tolerance and no need for hospitalization, and so improves quality of life and reduces health care costs.
活动能力下降以及糖皮质激素作为辅助治疗会导致杜氏肌营养不良症患者出现骨质疏松。阿仑膦酸钠已用于其他病因的儿童骨质疏松症，效果良好且无不良反应。
三名杜氏肌营养不良症患者，有骨骼受累症状（既往有全身性骨痛和骨折病史），通过双能X线吸收法测定骨矿物质密度（BMD），Z值≤ -2标准差。开始口服阿仑膦酸钠治疗（10毫克/天）。
所有病例腰椎（L2 - L4）骨密度均增加，骨痛有所改善。随访期间未观察到骨折和不良反应。
口服阿仑膦酸钠可使这些患者的骨密度增加，耐受性良好且无需住院，从而改善生活质量并降低医疗成本。
